Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB142 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A [Single Ascending Dose (SAD)]: BIIB142 Cohort 1A | EXPERIMENTAL | Participants will receive Dose A of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 2A | EXPERIMENTAL | Participants will receive Dose B of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 3A | EXPERIMENTAL | Participants will receive Dose C of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 4A | EXPERIMENTAL | Participants will receive Dose D of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 5A | EXPERIMENTAL | Participants will receive Dose E of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 6A | EXPERIMENTAL | Participants will receive BIIB142 on Day 1 in the fasted followed by fed state in the first sequence, and vice versa in the second sequence. A washout period of 14 days will be maintained between both the sequences. Dose will be determined based on emerging PK data. |
| Part B [Multiple Ascending Dose (MAD)]: BIIB142 Cohort 1B | EXPERIMENTAL | Participants will receive Dose A of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state. |
| Part B (MAD): BIIB142 Cohort 2B | EXPERIMENTAL | Participants will receive Dose F of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state. |
| Part B (MAD): BIIB142 Cohort 3B | EXPERIMENTAL | Participants will receive Dose D of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state. |
| Name | Type | Description |
|---|---|---|
| BIIB142 | DRUG | Administered Orally |
| BIIB142-Matching Placebo | DRUG | Administered Orally |
Key Inclusion Criteria: * Have a body mass index between 18 and 32 kilograms per square meter (kg/m\^2), inclusive, at screening. * Weight ≥ 50 kilograms (kg) at screening. * Negative polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in p...
BIIB142 is an investigational small molecule being studied in healthy volunteers. It is currently in a Phase 1 clinical trial to evaluate its safety and how it is processed in the body of healthy adult participants aged 18 to 55 years old. The drug is not approved for any condition and remains in clinical development.
BIIB142 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting a Phase 1 clinical trial to assess the safety and pharmacokinetics of BIIB142 in healthy volunteers.
BIIB142 is in Phase 1 clinical development. The ongoing trial is recruiting participants and is designed to study the safety of the drug and how it is processed in the body. As an investigational drug, BIIB142 has not been approved by regulatory authorities and is still in early-stage testing.
BIIB142 is being studied in one Phase 1 clinical trial with the identifier NCT07133828. This randomized, double-blind, controlled study is recruiting 78 healthy adult participants in the United States to evaluate the safety and processing of BIIB142 in the body.
BIIB142 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is studying the safety and how the drug is processed in healthy volunteers, and it has not yet been evaluated for efficacy or submitted for regulatory approval.